Chiesi Pharmaceuticals, Inc.
United States
7 articles about Chiesi Pharmaceuticals, Inc.
-
The FDA's agenda includes an advisory committee meeting for Sarepta's delandistrogene moxeparvovec, which, if approved, would become the first gene therapy for Duchenne muscular dystrophy.
-
2022 for Chiesi: The Group’s international growth continues
4/11/2023
The growth of Chiesi, a research-oriented international biopharmaceutical group headquartered in Parma and 31 Affiliates worldwide, continues.
-
Fabry disease treatment is going to get new updates as Protalix and Chiesi are seeking approval. This can be a game-changer in the market. Here's more about it.
-
It was a busy week for clinical trial announcements. Here's a look.
-
On December 28, the U.S. Food and Drug Administration reported there had been 50 novel drug approvals for the year, and that was just for new chemical entities.
-
Veloxis Pharma Announces Agreement With Chiesi Pharmaceuticals, Inc. To Commercialize Envarsus XR In China
6/7/2017
-
Chiesi Group Reports Financial Results For 2005: Marked Growth Driven By The Pipeline Products
3/7/2006